WuXi Biologics signs to expand a new state-of-the-art integrated biologics conjugation solution center to include commercial manufacturing in Wuxi National Hi-tech District. [Photo/wnd.gov.cn]

WuXi Biologics, a Wuxi-based global open-access biologics technology platform company, announced on June 20 that it plans to expand a new state-of-the-art integrated biologics conjugation solution center to include commercial manufacturing in Wuxi National Hi-tech District.

Bioconjugates such as Antibody-Drug Conjugates (ADCs) present new and exciting opportunities in treating various cancers.

Last June, WuXi Biologics announced the building of an integrated biologics conjugation solution center, including process development and clinical manufacturing for ADC drug substances and products.

This center is expected to initiate GMP manufacturing later this year. The new 5.5-acre expansion will enable cGMP commercial manufacturing for ADC drug substances and products.

Wuxi Mayor Huang Qin (right) attends the center's signing ceremony. [Photo/wnd.gov.cn]

Wuxi Mayor Huang Qin attended the center's signing ceremony and said Wuxi will continue to support the development of biologics technology and attract more innovation projects to invest in the city.

"We are quite excited to expand construction of this new integrated biologics conjugation solution center, which will further enhance our technical capabilities and manufacturing capacity in the fast-growing bioconjugation field," said Chen Zhisheng, CEO of WuXi Biologics.

"With the strength of our ONE-stop service platform covering antibodies, bioconjugation drug substances and products, WuXi Biologics will continue enabling our global partners to develop exciting ADCs to benefit cancer patients worldwide."

There are currently more than 20 ADCs being developed at WuXi Biologics. So far, WuXi Biologics has successfully advanced 11 ADC projects to Investigational New Drug (IND) filing.